Navidea Biopharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference

– CEO to Provide Business and Development Program Updates –

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB) today announced that Dr. Mark Pykett, President and Chief Executive Officer, will participate at the 14^th Annual BIO CEO & Investor Conference, hosted by the Biotechnology Industry Organization (BIO), on February 13-14 at the Waldorf Astoria in New York City. Dr. Pykett will provide an update of the Company and its development programs on Monday February 13, 2012 at 11:30 AM EST.

Investors and the public are invited to listen to a live webcast of Dr. Pykett’s presentation at http://www.veracast.com/webcasts/bio/ceoinvestor2012/44108579.cfm. Following the conference, the webcast will be archived for approximately 30 days.

About Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing three radiopharmaceutical agent platforms – Lymphoseek^®, AZD4694 and RIGScan^TM – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and ultimately patient care. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.

About the BIO CEO & Investor Conference

The 14^th Annual BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies. This year’s conference will feature corporate presentations from more than 130 leading biotechnology and pharmaceutical companies, three Fireside Chats with industry leaders, four Therapeutic Workshops and three Business Roundtables all drawing from seasoned industry executives and analysts. Additionally, the plenary sessions will address timely business issues and industry trends. Attendees can expect many opportunities to schedule one-on-one meetings as well as numerous networking opportunities. The conference is designed to foster an informative dialogue between institutional investors and senior biotechnology executives about emerging and current investment opportunities.